Direct intratumoral (i.t.) injection of adenoviruses (Ads) expressing specific immunostimulatory cytokines represents an attractive strategy for the clinical implementation of cytokine gene therapy of cancer. Interleukin-12 (IL-12) is a heterodimeric cytokine produced by antigen-presenting cells and promotes a T helper 1-like immune response. We have constructed an Ad vector (AdCMV-mIL-12) containing both chains of the murine IL-12 (mIL-12) gene linked by an internal ribosomal entry site sequence under the transcriptional control of the cytomegalovirus immediate-early gene promoter, which is able to mediate the transient expression of very high levels of biologically active mIL-12 both in vitro and in vivo. An i.t. injection of 4 ϫ 10 8 plaque-forming units of AdCMV-mIL-12 resulted in a complete regression of day 7 established subcutaneous MC38 murine adenocarcinomas and MCA205 murine fibrosarcomas. Treated animals rejected a subsequent rechallenge with MC38 and MCA205, respectively, demonstrating the induction of long-lasting antitumor immunity. Specific antitumor cytotoxic T lymphocyte reactivity was detected in splenocytes harvested from treated animals. A significant increase in the numbers of both CD4 ϩ and CD8 ϩ T cells in the AdCMV-mIL-12-infected tumors was observed. Ad-mediated IL-12 gene therapy was also associated with measurable serum levels of mIL-12 and profound changes in the composition of splenic lymphocytes. Taken together, these results demonstrate the feasibility and efficacy of delivering IL-12 directly i.t. using a recombinant adenoviral vector.
B iological therapy of cancer involves the systemic administration of recombinant cytokines, including interferon-␣ (IFN-␣) and interleukin-2 (IL-2).
1,2 The rationale for biological therapy is to amplify an already established but ineffective antitumor immune response or to elicit new effector cells. A limitation of such treatment modalities is the toxicity associated with the systemic administration of such agents. This is also true for IL-12, which seems to be important for the induction of cellular immune responses. The systemic administration of recombinant IL-12 protein has shown profound antitumor effects in animal models, but its clinical application has been associated with significant side effects. [3] [4] [5] IL-12 is a heterodimeric cytokine produced predominantly by antigen (Ag)-presenting cells in response to infectious agents. IL-12 induces IFN-␥ production from natural killer (NK) and T cells, stimulates the proliferation of activated NK and T cells, and enhances the cytotoxic activity of NK cells. Importantly, IL-12 promotes the generation of cytotoxic T lymphocytes (CTLs) through the induction of a T helper 1 (Th1)-like phenotype, which is characterized by high IFN-␥ production, and the Ag-specific differentiation of naive CD4
ϩ T cells. 6, 7 On a molecular level, Th1 cells are characterized by selective expression of the IL-12 receptor ␤2 subunit. 8 Recently, dendritic cells (DCs) have been shown to be critical for the induction of cellular immune responses. 9 -11 They produce high levels of IL-12 upon Ag-specific interactions with CD4 ϩ T cells mediated via CD40-CD40 ligand interactions, 12, 13 thereby directing a Th1-like immune response.
In vivo production of IL-12 locally to the tumor has been achieved without systemic side effects through the adoptive transfer of tumor cells or fibroblasts genetically modified in vitro to express the IL-12 genes. Intratumoral (i.t.) delivery of cells genetically modified to express IL-12 suppressed tumor outgrowth in mice in a dose-dependent manner and induced a cell-mediated antitumor immune response. Importantly, day 7 established mouse tumors could be treated by a direct i.t. injection of IL-12 gene-modified tumor cells or fibro-blasts. 14 -16 A clinical trial using a direct injection of tumors with cultured autologous fibroblasts transduced with a retroviral vector encoding both chains of human IL-12 is currently in progress for the treatment of patients with metastatic melanoma, breast, and head and neck cancer. [17] [18] [19] Novel gene transfer systems are now being developed to allow in vivo transduction and to overcome the time-consuming and costly need for ex vivo culture and manipulation of tumor cells or fibroblasts before the administration of the potential vectors for in vivo gene delivery. In this regard, much attention has been focused recently on the use of replication-deficient adenovirus (Ad) vectors. These vectors can be produced in very high titers (Յ10 12 -10 13 plaque-forming units (PFU)/mL), transduce a broad range of host cells, are highly infectious for both replicating as well as nonreplicating cells, and allow transient, high-level gene expression in vitro and in vivo without integration of vector sequences in the genome. We have constructed a replication-deficient Ad vector that contains both of the chains of the murine IL-12 (mIL-12) gene in the E1-deleted region linked by an intervening internal ribosomal entry site (IRES) sequence 11 under the transcriptional control of the immediate-early gene promoter of cytomegaloviruses (CMVs). This vector is able to mediate the transient production of high levels of biologically active mIL-12 in vitro and in vivo. Injection i.t. resulted in a regression of day 7 established subcutaneous (s.c.) MC38 adenocarcinomas as well as MCA205 fibrosarcomas, with an increase of CD4 ϩ and CD8 ϩ T cells infiltrating the tumor. Moreover, the tumor-specific CTL reactivity associated with long-lasting antitumor immunity was induced. Thus, i.t. delivery of IL-12 by a direct injection of a recombinant adenoviral vector is highly effective in treating established tumors.
MATERIALS AND METHODS

Mice and cell lines
Female C57BL/6 mice, 6 -10 weeks old, were obtained from Taconic Farms (Germantown, NY). Animals were maintained at the Biotechnology Center Animal Facility at the University of Pittsburgh. MC38, a murine colon adenocarcinoma cell line, and MCA205, a methylcholanthrene-induced murine fibrosarcoma, were generously provided by Dr. S.A. Rosenberg (National Cancer Institute, National Institutes of Health, Bethesda, Md) and maintained in RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf serum, 2 mM L-glutamine, 100 international units (IU)/mL penicillin, and 100 g/mL streptomycin (complete medium) (all reagents were obtained from Life Technologies, Gaithersburg, Md). A total of 293 cells were purchased from American Type Culture Collection (Manassas, Va) and maintained in Dulbecco's modified Eagle's medium supplemented with 10% heat-inactivated fetal calf serum, 2 mM L-glutamine, 50 M hydroxyethyl piperazine ethane sulfonic acid, 100 IU/mL penicillin, and 100 g/mL (Life Technologies, Gaithersburg, Md).
Recombinant adenoviral vectors
The Ad shuttle vector pAdCMV-B was used to generate early region 1-deleted recombinant Ads. pAdCMV-B carries the Ad type 5 sequences from nucleotides 1-355 and nucleotides 3328 -5788, containing the left end-inverted terminal repeat and packaging sequences and the recombination region, respectively. The transgene is driven by the CMV immediateearly gene promoter and is terminated by the simian virus 40 poly(A) signal. pAdCMV-mIL-12 (Fig 1) was constructed by transferring a BglII/BamHI fragment containing the p40 subunit of mIL-12 into the BamHI site of pAdCMV-B. A BamHI fragment containing the p35 encoding gene preceded by an encephalomyocarditis virus IRES (derived from DFG-mIL-12 14 ) was subsequently cloned in the BamHI site behind the p40 subunit. This resulted in a polycistronic message that expresses both subunits of mIL-12.
The E1-, E3-deleted Ad AdCMV-mIL-12 was generated using the method of Chinnadurai et al. 20 Briefly, the plasmid pAdCMV-mIL-12 was linearized at the AscI site and cotransfected into 293 cells with ClaI-digested AdLacZ0.10 DNA. Virus generated by recombination between the shuttle vector and the Ad DNA was plaque-purified and -propagated on 293 cells. 21 Viruses were purified from infected cells at 2 days after infection by three freeze-thaw cycles followed by three successive bandings on CsCl gradients. Purified virus was dialyzed against a buffer containing 10 mM tris(hydroxymethyl)aminomethane (pH 7.8), 150 mM NaCl, 10 mM MgCl 2 , and 3% sucrose, and was stored at Ϫ70°C until use. The contaminating replication-competent Ad level was Ͻ1 in 1 ϫ 10 7 PFU for AdCMV-mIL-12.
Bioassay for mIL-12
The bioactivity of the mIL-12 produced by cells transduced with AdCMV-mIL-12 was assessed by measuring the induction of IFN-␥ from freshly isolated splenocytes. Spleens were harvested and minced, a single-cell suspension was prepared by filtration through sterile nylon mesh, and red blood cells were lysed. Splenocytes were washed twice and seeded in 24-well plates at 2 ϫ 10 6 /well in 2 mL of complete medium containing different amounts of supernatants from AdCMV-mIL-12-infected tumor cells. After 48 hours, the supernatant was collected and tested for IFN-␥ release by enzyme-linked immunosorbent assay (ELISA).
ELISA for mIL-12 and mIFN-␥ ELISAs were established using the sandwich technique as follows: 96-well microtiter ELISA plates (Dynatech Immulon 2, Chantilly, Va) were coated with either monoclonal rat anti-mouse IL-12 p70 (clone 9A5, kindly provided by Hoffmann La Roche, Nutley, NJ) or rat anti-mouse IFN-␥ monoclonal antibody (mAb) (PharMingen San Diego, Calif) at a concentration of 4 g/mL in a 100 mM sodium carbonate buffer, pH 9.5 (16 hours at 4°C). Microtiter plates were then incubated with 3% (wt/vol) bovine serum albumin (BSA), 0.01% thimerosal (wt/vol), and 0.05% (vol/vol) Tween 20 in phosphate-buffered saline (PBS) (8 -24 hours at 4°C) to block unspecific binding; samples were subsequently incubated along with 2-fold dilutions of a known standard amount of recombinant mIL-12 (kindly provided by Hoffmann-La Roche) or mIFN-␥ (Pharmingen) in PBS containing 1% (wt/vol) BSA and 0.05% (vol/vol) Tween 20 (16 hours at 4°C). For detection, either peroxidase-conjugated monoclonal rat anti-mouse IL-12 p40 (clone 5C3, kindly provided by Hoffmann-La Roche) or biotinylated rat anti-mouse IFN-␥ antibody (Ab) (Pharmingen) was used at a concentration of 1 g/mL in PBS containing 1% (wt/vol) BSA and 0.05% (vol/vol) Tween 20 (2 hours at room temperature). The latter was followed by peroxidaseconjugated streptavidin (Boehringer Mannheim, Indianapolis, Ind) at a dilution of 1:20,000 in PBS containing 1% (wt/vol) BSA and 0.05% (vol/vol) Tween 20 (30 minutes at room temperature). The 3,3Ј,5,5Ј-tetramethylbenzidine microwell peroxidase substrate system (Kierkegaard and Perry Laboratories, Gaithersburg, Md) was used for color development, the reaction was stopped with 1N H 2 SO 4 , and plates were read at 450 nm with a Dynatech MR500 ELISA plate reader.
Murine tumor models
The mice used in the experiments were ear-tagged and randomized before inoculation with tumors. Tumor cells were inoculated intradermally in the shaved area of the left flank, and tumor establishment was determined by palpation. Tumor size was determined by measuring perpendicular tumor diameters with a vernier caliper. All measurements were completed in a coded, blinded fashion. Treatment groups consisted of five mice per group. Each experiment was performed at least twice with similar results. Representative experiments are shown. Results are reported as mean tumor area (mm 2 ).
Immunophenotyping
For immunophenotyping, splenocytes were washed in Hanks buffered saline solution supplemented with 1% BSA and 0.1% NaN 3 and incubated (30 minutes at 4°C) with one of the following mAbs: fluorescein isothiocyanate (FITC)-conjugated anti-I-A b , phycoerythrin (PE)-conjugated anti-mouse B7-1, PE-conjugated anti-mouse B7-2 (clone GL1), PE-conjugated anti-mouse CD11b, FITC-conjugated anti-CD3, PE-conjugated anti-NK1.1, and FITC-conjugated anti-B220 (all from Pharmingen). Splenocytes were also stained with the corresponding isotype-matched control mAb. Surface expression was analyzed using a FACScan flow cytometer (Becton Dickinson, Mountain View, Calif); data were collected on 10,000 viable cells.
Cytotoxicity assays
Spleens from immunized mice or from nonimmunized littermates were harvested and pooled. A total of 10 6 cells were restimulated with 4 ϫ 10 4 irradiated (20 krad) MC38 tumor cells and 3 ϫ 10 6 irradiated (3 krad) splenocytes as feeder cells in 2 mL of complete medium per well of a 24-well plate containing 20 IU/mL recombinant human IL-2 (Chiron, Emeryville, Calif). In vitro-restimulated lymphocytes were tested for their cytolytic reactivity against MC38 tumor cells or lymphokine-activated killer/NK-sensitive YAC lymphoma cells in standard 4-hour 51 Cr release assays using 96-well roundbottom plates. A total of 2 ϫ 10 6 target cells were radiolabeled with 100 Ci of Na 2 51 CrO 4 (DuPont New England Nuclear, Bedford, Mass) for 1 hour at 37°C. The percentage of specific 51 Cr release was calculated as 100 ϫ ([experimental release Ϫ spontaneous release]/[maximum release Ϫ spontaneous release]). Target cells incubated in medium alone or in medium containing 5% Triton X-100 were used to determine spontaneous and maximum 51 Cr release, respectively.
Immunohistochemistry
Animals were sacrificed at 14 days after tumor inoculation (7 days after i.t. treatment with recombinant Ads), and tumor tissue was collected and snap-frozen in liquid nitrogen. Slides were fixed briefly in ice-cold acetone, air-dried, rehydrated in PBS, and incubated in protein-blocking solution (Shandon, Pittsburgh, Penn). Staining with primary Ab (10 g/mL in PBS) for 1 hour at room temperature was followed by incubation with a biotinylated secondary Ab (Vector Laboratories, Burlingame, Calif) and peroxidase-conjugated streptavidin (Boehringer Mannheim) for 30 minutes each. Endogenous peroxidase was blocked with 0.5% (vol/vol) H 2 O 2 in methanol after incubation with the primary Ab. Extensive washings with PBS were performed between all steps. Color development was carried out using 3-amino-9-ethylcarbazole.
RESULTS
Expression of high levels of biologically active mIL-12 in AdCMV-mIL-12-transduced cells in vitro A recombinant adenoviral vector carrying both subunits of mIL-12 was constructed by recombination in 293 cells using the shuttle plasmid pAdCMV-mIL-12. The cDNA for the two subunits of mIL-12 was inserted into the shuttle plasmid and linked by the encephalomyocarditis virus IRES, allowing the expression of both p40 and p35 from a single polycistronic message (Fig 1) . To test the biological activity of the mIL-12 expressed from recombinant AdCMV-mIL-12, MC38 tumor cells were transduced in vitro. A total of 5 ϫ 10 5 cells were seeded in 75-cm 2 flasks 24 hours before infection with AdCMVmIL-12 or AdCMV-lacZ as a control. Supernatants were collected at 48 hours after infection, and the production of high levels of mIL-12 by AdCMV-mIL-12-infected tumor cells was confirmed by ELISA (Fig 2A) . The bioactivity of mIL-12 was assessed by measuring the stimulation of IFN-␥ release from freshly isolated murine splenocytes. Supernatant containing the mIL-12 produced by AdCMV-mIL-12-infected tumor cells induced significant IFN-␥ release from splenocyte re-sponders in a dose-dependent manner (Fig 2B) , demonstrating that the mIL-12 was biologically active. Figure 3 , A and B, MC38 tumors regressed in all animals that received AdCMV-mIL-12 i.t. A significant percentage (80%) of animals remained tumor-free for 60 days and rejected a subsequent rechallenge with 3 ϫ 10 5 MC38 tumor cells at this time; animals treated with AdCMV-mIL-12 in the contralateral flank displayed delayed tumor outgrowth, but 80% of these animals eventually developed tumors, suggesting that local, i.t. delivery of AdCMV-mIL-12 was more effective in inducing an antitumor response. In contrast, all animals that received AdCMV-lacZ developed tumors. Similar to the results with MC38, the MCA205 tumors infected with AdCMV-mIL-12 regressed (Fig 3C) . Again, 80% of the animals remained tumor-free ( Fig  3D) and resisted a rechallenge at 60 days after initial tumor challenge with 3 ϫ 10 5 MCA205 tumor cells. These results demonstrate the ability of an i.t. injection of AdCMV-mIL-12 to induce a strong antitumor response against two unrelated murine tumors.
An i.t. injection of recombinant
Successful treatment with AdCMV-mIL-12 results in the induction of antitumor CTL reactivity
To investigate whether AdCMV-mIL-12 treatment of animals bearing established MC38 tumors resulted in the induction of tumor-specific CTL responses, splenocytes were harvested from cured animals and restimulated with irradiated tumor cells in vitro. Cytotoxic reactivity could be detected against MC38 but not against lymphokine-activated killer/NK-sensitive YAC-1 cells (Fig 4A) . This reactivity could be partially inhibited by the addition of anti-CD8 mAb, but not anti-CD4 mAb (Fig 4B) , suggesting that tumor-specific CD8 ϩ CTLs were generated. In contrast, no cytolytic activity was observed in restimulated splenocytes harvested from naive animals (data not shown). This observation is consistent with the inability to establish tumors upon the rechallenge of treated animals with tumor.
An i.t. injection of AdCMV-mIL-12 increases the number of infiltrating CD4
ϩ and CD8 ϩ T cells
To further understand the mechanism of AdCMV-mIL-12-mediated antitumor responses, tumor sections at 3 and 7 days after AdCMV-mIL-12 administration were analyzed for the presence of infiltrating T cells as well as DCs. As shown in Figure 5 , a significant increase in both CD4 ϩ and CD8 ϩ T cells was observed at day 7, with a similar increase observed on day 3 (data not shown). There also seems to be a slight increase in the number of NLDC145-positive DCs in the tumor at day 7. These histological data showing increased CD4 ϩ and CD8 A: A total of 10 6 MC38 tumor cells were infected with recombinant AdCMV-mIL-12 or AdCMV-lacZ using the indicated multiplicity of infection (MOI). At 48 hours after infection, supernatants were harvested and the production of high levels of mIL-12 was confirmed by ELISA. B: To assess biological activity, the mIL-12-containing supernatants were incubated with freshly isolated splenocytes; the induction of mIFN-␥ release was measured by ELISA. One representative experiment of three is shown.
An i.t. injection of AdCMV-mIL-12 results in measurable serum levels and changes in splenic lymphocyte populations To determine whether an i.t. injection results in elevated circulating levels of mIL-12, sera from AdCMV-mIL-12-treated animals was analyzed for mIL-12 and IFN-␥. As shown in Table 1 , an injection of AdCMV-mIL-12 but not AdCMV-lacZ resulted in a consistent increase in the serum levels of mIL-12 and IFN-␥. Moreover, an i.t. injection of AdCMV-mIL-12 resulted in marked changes in splenic lymphocyte populations. Splenocytes harvested 7 days after AdCMV-mIL-12 injection were immunophenotyped using a panel of mAbs. Although the spleens of AdCMV-mIL-12-treated mice contained ϳ2-to 5-fold more cells, the absolute number of T cells (CD3 ϩ ) and B cells (B220 ϩ ) was unchanged. However, the number of NK cells (NK1.1 ϩ ), macrophages (CD11b ϩ ), and DCs (I-A bϩ and B7-2 ϩ ) was markedly increased (Fig 6) . More than one-third of the splenocytes did not stain with any of these lineage-restricted markers, suggesting the occurrence of extramedullary hematopoiesis induced by IL-12.
6
DISCUSSION
In this report, we describe the development and application of a recombinant Ad expressing mIL-12 for cancer gene therapy. We have constructed an adenoviral vector in which, instead of the two subunits of IL-12 being expressed from two different promoters, both genes are expressed from a single polycistronic message using an IRES. This AdCMV-mIL-12 vector expressed high levels of biologically active mIL-12 in vitro as well as in vivo. In two different, unrelated murine tumor model systems (MC38 adenocarcinoma and MCA205 fibrosarcoma), strong antitumor effects were observed following an i.t. injection on day 7 of AdCMV-mIL-12. Indeed, 100% of the AdCMV-mIL-12-treated tumors regressed, with 80% of the animals becoming tumor-free. The treated animals were also immune to subsequent rechallenge, indicating the induction of long-lasting tumor immunity. Because measurable serum levels of mIL-12 were detected following an i.t. injection of AdCMVmIL-12, it was not clear whether the strong antitumor responses were attributable to locally or systemically expressed mIL-12. We have attempted to address this question by injecting AdCMV-mIL-12 into the contralateral flank to determine whether elevated serum levels resulted in tumor regression. We observed that injecting the virus contralaterally only partially reduced tumor growth and appears not to result in the effective induction of long-lasting antitumor immunity. Thus, although the antitumor response seems to be partially mediated by elevated systemic levels of IL-12, the results suggest that local IL-12 expression i.t. induces a more potent antitumor immunity. In addition, the delivery of IL-12 to tumors using a direct injection of Ad is far easier than ex vivo manipulation using genetically modified fibroblasts.
Because IL-12 is known to be critical for the induction of cellular immune responses, we examined the cellular infiltration of regressing tumors and looked for tumorspecific CTLs in splenocyte populations in vitro following i.t. AdCMV-mIL-12 administration. Histological examination showed observed a significant increase in the numbers of CD4 ϩ and CD8 ϩ T lymphocytes in the tumors of AdCMV-mIL-12-treated animals compared with those of the AdCMV-lacZ-treated group; this finding is consistent with the observation that the i.t. delivery of mIL-12 resulted in an enhanced induction of cellular immunity and was further supported by the detection of CTL reactivity after in vitro restimulation of splenocytes harvested from AdCMV-mIL-12-treated animals, but not from AdCMV-lacZ-treated animals. Interestingly, Ad-mediated delivery of mIL-12 resulted in profound alterations of splenocyte subpopulations. Spleens of AdCMV-mIL-12-treated animals contained 2-to 5-fold more lymphocytes than did AdCMV-lacZtreated controls. The absolute numbers of NK cells, macrophages, and DCs were increased significantly, whereas the absolute number of T and B cells remained approximately the same. More than one-third of the splenocytes did not stain with any of the examined lineage-restricted markers, suggesting the occurrence of extramedullary hematopoiesis. A similar effect was observed in animals that were administered recombinant mIL-12 protein. 6 Thus, mIL-12 gene delivery by local injection of a recombinant Ad results in the induction of multiple systemic effects. In addition, we have prelimi- nary observations in an unrelated rat model of s.c. adenoviral gene transfer suggesting that a heterogenous population is infected, including tumor-infiltrating cells, and that DCs can be transduced that can potentially traffic to lymphoid organs (data not shown).
Several groups have examined the ability of adenovirally delivered cytokines such as IFN-␣, 22 IL-2, [23] [24] [25] [26] [27] IL-4, 28 and IL-12 29 -32 to induce antitumor responses. Bramson et al have constructed an adenoviral vector expressing the two IL-12 subunits from two different promoters; the dual promoter Ad-IL-12 vector was used to treat a murine tumor line derived from polyoma middle T Ag-positive mice. 31 They observed that Ͼ75%
of the Ad-IL-12-treated tumors showed either a complete or partial response, with an induction of antitumor immunity in the cured animals. Exactly why the efficiency of complete responses by Bramson et al is reduced compared with our results is unclear, but may reflect differences in IL-12 expression between the two vectors and/or in the tumor models used. Chen et al have recently reported the use of a bicistronic Ad-IL-12 vector, similar to the one used in this report, to treat a murine bladder carcinoma by i.t. injection. 32 They observed a complete regression in all treated tumors that was similar to what we have observed for MCA205 and MC38 tumors. Moreover, Chen et al observed that the ϩ and CD8 ϩ T cells. Tumor tissue was harvested 7 days after an i.t. injection of recombinant AdCMV-mIL-12 or AdCMV-lacZ, and cryosections were stained with anti-CD4, anti-CD8, and NLDC145 mAb. 
Ad-IL-12-mediated response is reduced in CD4
ϩ -and CD8 ϩ -deleted mice. Thus, their results correlate well with our experiments, demonstrating a significant CD4 ϩ and CD8 ϩ infiltrate within the tumor. Taken together, the results using an i.t. injection of an Ad-IL-12 vector demonstrate that local overproduction of IL-12 is effective in inducing a specific antitumor response against a variety of murine tumors. The immune response is dependent upon CD4 ϩ and CD8 ϩ T cells and possibly also upon DCs, which can be detected in the tumor with Ad-IL-12. Local i.t. delivery of Ad-IL-12 results in detectable systemic IL-12 levels and in the induction of systemic IFN-␥. Moreover, there is a significant effect on the splenocyte lymphocyte population, with increases in NK cells, macrophages, and DCs. However, there is no apparent toxicity associated with i.t. Ad-IL-12 delivery. Thus, adenoviral-mediated delivery of IL-12 locally by i.t. injection is highly effective in inducing specific antitumor immune responses and may be used clinically for the immunotherapy of patients with cancer. Figure 6 . AdCMV-mIL-12-treatment results in profound changes in the composition of splenic lymphocytes. Splenocytes were harvested 7 days after an i.t. injection of AdCMV-mIL-12 or AdCMVlacZ; immunophenotyping was performed for the indicated surface markers.
